Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Gross Profit (2016 - 2025)

Amicus Therapeutics' Gross Profit history spans 10 years, with the latest figure at $158.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 17.64% year-over-year to $158.7 million, compared with a TTM value of $561.3 million through Dec 2025, up 18.08%, and an annual FY2025 reading of $561.3 million, up 18.08% over the prior year.
  • Gross Profit for Q4 2025 was $158.7 million at Amicus Therapeutics, up from $149.6 million in the prior quarter.
  • The five-year high for Gross Profit was $158.7 million in Q4 2025, with the low at $59.9 million in Q1 2021.
  • Average Gross Profit over 5 years is $98.0 million, with a median of $89.5 million recorded in 2023.
  • Year-over-year, Gross Profit rose 0.6% in 2022 and then surged 37.07% in 2024.
  • Tracing FOLD's Gross Profit over 5 years: stood at $74.3 million in 2021, then rose by 5.93% to $78.7 million in 2022, then surged by 31.82% to $103.8 million in 2023, then rose by 29.99% to $134.9 million in 2024, then increased by 17.64% to $158.7 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Gross Profit are $158.7 million (Q4 2025), $149.6 million (Q3 2025), and $139.5 million (Q2 2025).